Arturo Estrella has a message for recession naysayers: It could hit sooner than you think.Marketsread more
Local governments commonly share single service providers, making many vulnerable at once. On top of this, ransomware has often been used to mask more targeted, malicious...Technologyread more
Salesforce released its first earnings report since its $15.3 billion acquisition of Tableau Software, the company's largest deal ever.Technologyread more
Fed Chairman Jerome Powell faces the tough challenge of presenting a unified voice on Fed policy from the most divided Fed in years.Market Insiderread more
Kudlow also confirmed to CNBC that he supported a tax cut proposal floated earlier Thursday by Sen. Rick Scott, R-Fla.Politicsread more
VMware is following through on its proposal to buy Pivotal, a fellow Dell subsidiary, and expanding into cybersecurity with the acquisition of Carbon Black.Technologyread more
Google says it shut down hundreds of YouTube channels tied to misinformation around the Hong Kong protests.Technologyread more
It is a rare scenario where long-term interest rates suddenly fall below short-term interest rates.Real Estateread more
Investors are rushing to get a piece of its privately held rival Impossible Foods before it goes public, according to the Wall Street Journal.Food & Beverageread more
Weisler has been CEO at the company since 2015 when it split from HPE.Technologyread more
Companies want to know our values and if they work with us, "they want to be aligned with those values," Salesforce co-CEO Keith Block says.Mad Money with Jim Cramerread more
U.S. drugmaker AbbVie has announced plans to takeover Dublin-based pharmaceutical company Shire in a deal worth around £32 billion ($54.7 billion), as AbbVie seeks to lower its tax rate by buying a foreign rival.
The Shire board has backed an offer that will be made up of £24.44 in cash and 0.8960 AbbVie share per Shire share, meaning AbbVie will pay about £52.48 per share for the specialist pharmaceutical firm.
Shire shareholders will end up owning 25 percent of the new merged group.
AbbVie said it expects the deal will cut its effective tax rate to approximately 13 percent.
Shire shares were up as much as 2.5 percent shortly after the deal was announced.
If the takeover is successful, North Chicago-based AbbVie plans to relocate the new combined firm in the U.K., allowing it to benefit from the country's lower tax.
Shire is the second FTSE-listed pharmaceutical firm that has been approached by a U.S. rival, after Pfizer's failed takeover bid for U.K. group Astra Zeneca.
The Shire Board, has been advised by Citi, Deutsche Bank, Evercore, Goldman Sachs and Morgan Stanley. Shire said the banks consider the terms of the transaction to be fair and reasonable.
Follow us on Twitter: